• linkedin
  • Increase Font
  • Sharebar

    Alpha-blocker may have benefit in larger stones

    While there is no benefit from using tamsulosin (Flomax) versus placebo for the treatment of small ureteral stones, there is a potential upside of increased passage from using the drug to treat 5- to 10-mm stones, according to a study from Australia published online in the Annals of Emergency Medicine (July 13, 2015).  

    First author Jeremy Furyk, MBBS, MPH, of Townsville Hospital, Townsville, Queensland, and colleagues studied 403 patients randomized to receive 0.4 mg of tamsulosin or placebo daily, for 28 days. Median stone size was 4.0 mm in the tamsulosin group versus 3.7 mm in the placebo group.

    Read: Stone patients are poorly adherent with medical prophylaxis

    They found no significant difference between the groups within 28 days of patients’ visits to the emergency department. Eighty-seven percent of those in the tamsulosin group and 81.9% of patients in the placebo group passed their stones. But in a subgroup analysis of large stones—5 to 10 mm—83.3% of tamsulosin participants had stone passage versus 61.0% of those receiving placebo.

    Otherwise, the authors found no differences in urologic interventions, time to self-reported stone passage, pain, analgesia needs, or adverse events, according to the study’s abstract.

    NEXT: Dr. Furyk's take-home message

    More on Stone Disease

    MET found safe, efficacious in pregnant stone patients

    Ultrasound stone repositioning facilitates passage

    Is billing for stone prevention counseling possible?

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available